Outcomes of central nervous system cryptococcosis vary with host immune function: Results from a multi-center, prospective study

Journal of Infection

Volumn 61, Issue 5, 2010, Pages 419-426

  Nguyen, M Hong ^a,b   Husain, Shahid ^b   Clancy, Cornelius J ^a,b,c   Peacock, James E ^d   Hung, Chien Ching ^e   Kontoyiannis, Dimitrios P ^f   Morris, Arthur J ^g   Heath, Christopher H ^h,i   Wagener, Marilyn ^b,c   Yu, Victor L ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f UNIVERSITY OF TEXAS   (United States)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h ROYAL PERTH HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cryptococcal meningitis; Cryptococcosis; HIV; Immunocompetent; Immunosuppressed

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE;

ADULT; APACHE; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCOSIS; FEVER; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MENTAL HEALTH; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY CRYPTOCOCCOSIS; SHUNTING;

ADULT; ANTIFUNGAL AGENTS; APACHE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CEREBROSPINAL FLUID SHUNTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; HIV INFECTIONS; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; UNITED STATES;

EID: 78149358512     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.08.004     Document Type: Article

References (34)

1. Bennett J.E., Dismukes W.E., Duma R.J., Medoff G., Sande M.A., Gallish H., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979, 301:126-131.
2. Dismukes W.E., Cloud G., Gallis H.A., Kerkering T.M., Medoff G., Craven P.C., et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334-341.
3. Chayakulkeeree M., Perfect J.R. Cryptococcosis. Infect Dis Clin North Am 2006, 20:507-544. v-vi.
4. Alexander B.D. Cryptococcosis after solid organ transplantation. Transpl Infect Dis 2005, 7:1-3.
5. Dromer F., Mathoulin S., Dupont B., Brugiere O., Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 1996, 22(Suppl. 2):S154-S160.
6. Kiertiburanakul S., Wirojtananugoon S., Pracharktam R., Sungkanuparph S. Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis 2006, 10:72-78.
7. Pappas P.G., Perfect J.R., Cloud G.A., Larsen R.A., Pankey G.A., Lancaster D.J., et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33:690-699.
8. Singh N., Dromer F., Perfect J.R., Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008, 47:1321-1327.
9. Vilchez R., Shapiro R., McCurry K., Kormos R., Abu-Elmagdk, Fung J., et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003, 16:336-340.
10. Wu G., Vilchez R.A., Eidelman B., Fung J., Kormos R., Kusne S. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transpl Infect Dis 2002, 4:183-188.
11. Chen J., Varma A., Diaz M.R., Litvintseva A.P., Wollenberg K.K., Kwon-Chung K.J. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 2008, 14:755-762.
12. Ecevit I.Z., Clancy C.J., Schmalfuss I.M., Nguyen M.H. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006, 42:1443-1447.
13. Lui G., Lee N., Ip M., Choi K.W., Tso Y.K., Lam E., et al. Cryptococcosis in apparently immunocompetent patients. QJM 2006, 99:143-151.
14. Munoz P., Giannella M., Valerio M., Giannella M., Valerio M., Soria T., et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 2007, 57:443-446.
15. Chen S., Sorrell T., Nimmo G., Speed B., Currie B., Ellis D., et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000, 31:499-508.
16. Kidd S.E., Bach P.J., Hingston A.O., Mak S., Chow Y., MacDougall L., et al. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg Infect Dis 2007, 13:51-57.
17. Kidd S.E., Hagen F., Tscharke R.L., Huynh M., Bartlett K.H., Fyfe M., et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004, 101:17258-17263.
18. Mitchell D.H., Sorrell T.C., Allworth A.M., Heath C.H., McGregor A.R., Papanaoum K., et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995, 20:611-616.
19. Speed B.R., Kaldor J., Cairns B., Pegorer M. Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjects. J Med Vet Mycol 1996, 34:187-193.
20. Hoang L.M., Maguire J.A., Doyle P., Fyfe M., Roscoe D.L. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004, 53:935-940.
21. Fraser J.A., Giles S.S., Wenink E.C., Geunes-Boyer S.G., Wright J.R., Diezmann S., et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005, 437:1360-1364.
22. Perfect J.R., Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002, 16:837-874. v-vi.
23. Loyse A., Wainwright H., Jarvis J.N., Bicanic T., Rebe K., Meintjes G., et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010, 24:405-410.
24. Thwaites G.E., Nguyen D.B., Nguyen H.D., Hoang T.Q., Do T.T., Nguyen T.C., et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741-1751.
25. Singh N., Lortholary O., Alexander B.D., Gupta K.L., John G.T., Pursell K., et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005, 40:1756-1761.
26. Skiest D.J., Hester L.J., Hardy R.D. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005, 51:e289-e297.
27. Phillips P., Chapman K., Sharp M., Harrison P., Vortel J., Steiner T., et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin Infect Dis 2009, 49:591-595.
28. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010, 50:291-322.
29. Breton G., Seilhean D., Cherin P., Herson S., Benveniste O. Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. Am J Med 2002, 113:155-157.
30. Sungkanuparph S., Jongwutiwes U., Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 2007, 45:595-596.
31. Singh N., Perfect J.R. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007, 7:395-401.
32. Nguyen T.H., Tran T.H., Thwaites G., Ly V.C., Dinh X.S., Ho Dang T.N., et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007, 357:2431-2440.
33. Prasad K., Singh M.B. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008, CD002244.
34. Casadevall A., Pirofski L.A. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003, 1:17-24.